Treatment of inflammatory bowel disease (IBD)

被引:297
|
作者
Pithadia, Anand B. [1 ]
Jain, Sunita [1 ]
机构
[1] LM Coll Pharm, Dept Pharmacol, Ahmadabad 380009, Gujarat, India
关键词
inflammatory bowel disease (IBD); 5-aminosalicylates; corticosteroids; infliximab; PLACEBO-CONTROLLED TRIAL; ACTIVE ULCERATIVE-COLITIS; RANDOMIZED CONTROLLED-TRIAL; FACTOR-KAPPA-B; ALOE-VERA GEL; CROHNS-DISEASE; DOUBLE-BLIND; ORAL BUDESONIDE; MEDICAL THERAPY; PILOT TRIAL;
D O I
10.1016/S1734-1140(11)70575-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.
引用
收藏
页码:629 / 642
页数:14
相关论文
共 50 条
  • [21] SMOKING AND INFLAMMATORY BOWEL-DISEASE (IBD)
    SANDLER, RS
    HOLLAND, KL
    GASTROENTEROLOGY, 1988, 94 (05) : A398 - A398
  • [22] Sirna therapy of inflammatory bowel disease (IBD)
    Cristofaro, Patricia
    Nasir, Amana
    Konkin, Tamako
    Hovanesian, Virginia
    Monfils, Paul R.
    Resnick, Murray B.
    Ramratnam, Bharat
    Moss, Steven F.
    GASTROENTEROLOGY, 2006, 130 (04) : A343 - A343
  • [23] Inflammatory Bowel Disease (IBD) Activity and Depression
    Duong, Nikki
    Hussain, Nadeen
    Kallus, Samuel
    Mattar, Mark
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1561 - S1562
  • [24] Inflammatory bowel disease (IBD) serological markers
    Benkhadra, F.
    Humbel, R. -L.
    IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2008, 23 (04): : 202 - 211
  • [25] Inflammatory Bowel Disease (IBD) in Northeast of Iran
    Semnani, S. H.
    Azarhoush, R.
    Abdolahi, N.
    Besharat, S.
    Roshandel, G. H.
    Jabbari, A.
    Roshandel, D.
    Kalavi, K. H.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2008, 2 (02) : 731 - 734
  • [26] Role of bacteria in Inflammatory bowel disease (IBD)
    Bharadwaj, R. S.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 134 - 134
  • [27] Innate immunogenetics and inflammatory bowel disease (IBD)
    McGovern, D
    Van Heel, D
    Negoro, K
    Lench, N
    Ahmad, T
    Jewell, D
    GASTROENTEROLOGY, 2003, 124 (04) : A369 - A369
  • [28] Genomic Testing in Inflammatory Bowel Disease (IBD)
    Arkwright, P.
    JOURNAL OF PATHOLOGY, 2021, 255 : S3 - S3
  • [29] Innate immunogenetics and inflammatory bowel disease (IBD)
    McGovern, DPB
    van Heel, DA
    Negoro, K
    Ahmad, T
    Jewell, DP
    GUT, 2003, 52 : A59 - A59
  • [30] Evolution of osteopenia in inflammatory bowel disease (IBD)
    Dinca, M
    Fries, W
    Luisetto, G
    Leone, L
    Martin, A
    GASTROENTEROLOGY, 1997, 112 (04) : A960 - A960